VTGN - Vistagen Therapeutics, Inc.
IEX Last Trade
2.56
0.010 0.391%
Share volume: 29,352
Last Updated: Thu 26 Dec 2024 08:30:02 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.55
0.01
0.39%
Fundamental analysis
28%
Profitability
43%
Dept financing
25%
Liquidity
25%
Performance
15%
Performance
5 Days
-0.78%
1 Month
-1.92%
3 Months
-15.00%
6 Months
-21.54%
1 Year
-52.07%
2 Year
2,510.03%
Key data
Stock price
$2.56
DAY RANGE
$2.40 - $2.60
52 WEEK RANGE
$2.36 - $5.74
52 WEEK CHANGE
-$51.34
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Shawn K. Singh
Region: US
Website: vistagen.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vistagen.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system. The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder.
Recent news